NCT06056037

Brief Summary

This study seeks to develop and pilot test a theory-based, integrated technology and counseling intervention to improve ART adherence among sexual and gender minority (SGM) young people living with HIV (ages 18-24) in Rio de Janeiro, Brazil. The intervention aims to improve social support, self-efficacy for taking ART, and teach skills for problem-solving barriers to promote better adherence.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
72

participants targeted

Target at P25-P50 for not_applicable hiv

Timeline
Completed

Started Oct 2023

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 19, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

September 28, 2023

Completed
3 days until next milestone

Study Start

First participant enrolled

October 1, 2023

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2026

Completed
Last Updated

September 19, 2025

Status Verified

September 1, 2025

Enrollment Period

2.6 years

First QC Date

September 19, 2023

Last Update Submit

September 15, 2025

Conditions

Keywords

Brazilsexual and gender minorityadolescentsHIVMedication adherence

Outcome Measures

Primary Outcomes (5)

  • Feasibility: number of participants who have at least one follow up visit

    Retention rate

    6 months

  • Feasibility: mean number of intervention sessions attended

    Session attendance (in intervention arm)

    3 months

  • Acceptability: mean score on the Client Satisfaction Questionnaire scale (CSQ-8)

    CSQ-8

    3 months

  • Medication adherence - proportion of participants with presence of tenofovir in urine using a point-of-care lateral flow immunoassay (LFA) method

    Presence of tenofovir in urine using a point-of-care lateral flow immunoassay (LFA) method

    6 months

  • Medication adherence - proportion who have received all ART prescriptions over the course of follow up according to pharmacy dispensing records (SICLOM national registry)

    pharmacy dispensing records via the SICLOM database

    6 months

Secondary Outcomes (2)

  • Plasma viral load - mean viral load as obtained through the SISCEL database (national registry)

    6 months

  • Retention in HIV care: proportion who have been in continuous care according to 1) at least 1 or more routine HIV visits, 3 months apart or more, (2) receiving 1 or more CD4 tests; and (3) receiving 1 or more viral load tests

    6 months

Study Arms (2)

Making ART Work

EXPERIMENTAL

A culturally tailored, theoretically grounded social support intervention that includes receipt of daily text messages and provider-facilitated group adherence counseling (4 sessions)

Behavioral: Experimental: Making ART WorkBehavioral: Standard of Care

Standard of Care

ACTIVE COMPARATOR

Standard clinical care referrals and basic medication adherence education

Behavioral: Standard of Care

Interventions

A culturally tailored, theoretically grounded provider-facilitated group-based social support intervention (4 sessions) that emphasizes a collective approach to ART adherence and includes establishing a common understanding of ART, identifying potential barriers to ART adherence with a focus on social and structural barriers (e.g., stigma, relationship influences, family support, economic stressors), developing practical strategies to increase self-esteem and self-efficacy to enhance ART adherence, and generating and maintaining peer norms and support for ART adherence within one's social group. These sessions will include SGM youth-specific video vignettes that address the social/contextual realities faced by SGM YLWH in Brazil. Lastly, the intervention includes daily SMS text messaging that serve as both reminders and cognitive cues to take medication as prescribed.

Making ART Work

Prior to randomization, all participants will meet briefly with a counselor to assess current needs for standard HIV primary care and referrals to social and/or health (including mental health) services. If participants do not have a primary HIV care provider, they will be linked to a provider at INI-Fiocruz or their preferred clinic, where they can access free HIV care through the no-cost universal access program of the Brazilian Public Health System. Additionally, the counselor will provide necessary referrals as needed, e.g., for social, general health and/or mental health services. Additionally, in order to provide a baseline level of standardized adherence information, all participants will receive a brief adherence educational session, which consists of a review of medications and recommended dosing, adherence expectations, toxicity expectations, and medication misperceptions.

Making ART WorkStandard of Care

Eligibility Criteria

Age18 Years - 24 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • between 18 and 24 years of age
  • assigned male sex at birth
  • identify as a gay or bisexual man, or a transgender woman or another gender identity along the feminine spectrum
  • self-report living with HIV, and verified by medical chart review,
  • self-report currently taking or prescribed ART for \> 3 months
  • self-report missing 2 or more doses of ART medications in any given week in the past month OR not virally suppressed (i.e., \>40 copies/mL in past 3 months; via national outpatient data \[SISCEL\] or plasma viral load testing)
  • owns a cell phone or willing to use one as part of the study

You may not qualify if:

  • unable to give informed consent due to cognitive limitation, severe mental/physical illness or intoxication
  • unable to read and/or write to an extent that would limit their ability to comprehend the informed consent
  • lived in the greater Rio de Janeiro area for \< 3 months or planning to move outside the area within the next year

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Evandro Chagas National Institute of Infectious Diseases (INI) Oswaldo Cruz Foundation (FIOCRUZ)

Rio de Janeiro, Brazil

RECRUITING

MeSH Terms

Conditions

Acquired Immunodeficiency SyndromeMedication AdherenceCoitus

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

HIV InfectionsBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesSlow Virus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesPatient CompliancePatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehaviorSexual Behavior

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Officials

  • Katie Biello, PhD, MPH

    Brown University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Katie Biello, PhD, MPH

CONTACT

Jennifer Olson, MBA

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
The PIs nor the individual conducting outcome assessments will know the status of the participants' randomization.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Pilot randomized controlled trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 19, 2023

First Posted

September 28, 2023

Study Start

October 1, 2023

Primary Completion

April 30, 2026

Study Completion

April 30, 2026

Last Updated

September 19, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will share

Raw data for additional analysis will be available to outside individuals through contacting the MPIs at two different times. The first will be after all of the baseline data is collected. We will institute a concept plan process where internal study staff first have the availability to write primary papers or give presentations on particular topics. After this, if outside individuals wish to analyze data, we will welcome this collaboration. A similar process will happen for outcome data; however this will not be possible until the publication and release of the outcome paper(s). The PI will store the data indefinitely and allow access for pooled data analysis projects, or projects for outside individuals. Information regarding the availability of data for analysis will be listed on the MPIs' web pages. Contact information for the PI will be listed in all manuscripts and publications as another means to access data.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Raw data for additional analysis will be available to outside individuals through contacting the MPIs at two different times. The first will be after all of the baseline data is collected. We will institute a concept plan process where internal study staff first have the availability to write primary papers or give presentations on particular topics. After this, if outside individuals wish to analyze data, we will welcome this collaboration. A similar process will happen for outcome data; however this will not be possible until the publication and release of the outcome paper(s). The PI will store the data indefinitely and allow access for pooled data analysis projects, or projects for outside individuals.

Locations